These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10037187)

  • 1. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
    Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
    Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and metastasis marker of human tumors.
    Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
    Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
    Tabata M; Kondo M; Haruta Y; Seon BK
    Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
    Tsujie M; Uneda S; Tsai H; Seon BK
    Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
    Tsujie M; Tsujie T; Toi H; Uneda S; Shiozaki K; Tsai H; Seon BK
    Int J Cancer; 2008 May; 122(10):2266-73. PubMed ID: 18224682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
    Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
    Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
    Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
    Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
    She X; Matsuno F; Harada N; Tsai H; Seon BK
    Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
    Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin-targeted cancer therapy.
    Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y
    Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
    Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
    Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
    Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
    Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
    Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
    Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.
    Shiozaki K; Harada N; Greco WR; Haba A; Uneda S; Tsai H; Seon BK
    Cancer Immunol Immunother; 2006 Feb; 55(2):140-50. PubMed ID: 15856228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.